These innovative molecules represent a significant leap in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose levels. https://mariamfnsm537698.blogspothub.com/37990389/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide